Author:
Tuffaha Muin S. A.,Guski Hans,Kristiansen Glen
Publisher
Springer International Publishing
Reference8 articles.
1. Fanburg-Smith JC, Bratthauer GL, Miettinen M, M. Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: a study of 28 cases. Hum Pathol. 1999;30(1):32–8.
2. Wittenburg G, Volkel C, Mai B, Lauer G. Immunohistochemical comparison of differentiation markers on paraffin and plastic embedded human bone samples. J Physiol Pharmacol. 2009;60(Suppl 8):43–9.
3. Conner JR, Hornick JL. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology. 2013;63(1):36–49.
4. Machado I, Navarro S, Picci P, et al. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas. Pathol Res Pract. 2016;212(9):811–6.
5. Davis JL, Horvai AE. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas. Histopathology. 2016;69(1):84–90.